ALNY (STOCKS)
Alnylam Pharmaceuticals, Inc.
$321.800000
-1.180000 (-0.37%)
Prev close: $322.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Yvonne L. Greenstreet
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $42,514.29M
- Employees
- 2,230
- P/E (TTM)
- 1,343.51
- P/B (TTM)
- 181.99
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
19
Buy
9
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$2.11 | $0.76 | +1.3487 | +177.16% |
|
Jun 2025 (Q2)
|
$-0.51 | $-0.73 | +0.2249 | +30.60% |
|
Mar 2025 (Q1)
|
$-0.44 | $-1.03 | +0.5883 | +57.21% |
|
Dec 2024 (Q4)
|
$-0.65 | $-0.64 | -0.0140 | -2.20% |
Financial Statements
| Revenues | $3.21B |
| Benefits Costs and Expenses | $3.24B |
| Cost Of Revenue | $512.09M |
| Costs And Expenses | $2.95B |
| Gross Profit | $2.70B |
| Nonoperating Income/Loss | -$296.64M |
| Operating Expenses | $2.43B |
| Selling, General, and Administrative Expenses | $1.18B |
| Research and Development | $1.25B |
| Other Operating Expenses | $4.87M |
| Operating Income/Loss | $264.70M |
| Income/Loss From Continuing Operations After Tax | $43.57M |
| Income/Loss From Continuing Operations Before Tax | -$31.94M |
| Income Tax Expense/Benefit | -$75.51M |
| Income Tax Expense/Benefit, Deferred | -$82.42M |
| Net Income/Loss | $43.57M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $43.57M |
| Net Income/Loss Available To Common Stockholders, Basic | $43.57M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.33 |
| Diluted Earnings Per Share | $0.30 |
| Basic Average Shares | 131,082,000 |
| Diluted Average Shares | 134,638,000 |
| Assets | $4.85B |
| Current Assets | $3.95B |
| Inventory | $75.38M |
| Other Current Assets | $3.88B |
| Noncurrent Assets | $898.85M |
| Fixed Assets | $501.75M |
| Other Non-current Assets | $397.10M |
| Liabilities | $4.62B |
| Current Liabilities | $1.56B |
| Accounts Payable | $117.59M |
| Other Current Liabilities | $1.44B |
| Noncurrent Liabilities | $3.06B |
| Equity | $233.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $233.89M |
| Liabilities And Equity | $4.85B |
| Net Cash Flow From Operating Activities | $265.86M |
| Net Cash Flow From Operating Activities, Continuing | $265.86M |
| Net Cash Flow From Investing Activities | $420.59M |
| Net Cash Flow From Investing Activities, Continuing | $420.59M |
| Net Cash Flow From Financing Activities | -$319.51M |
| Net Cash Flow From Financing Activities, Continuing | -$319.51M |
| Exchange Gains/Losses | $23.37M |
| Net Cash Flow | $390.30M |
| Net Cash Flow, Continuing | $366.94M |
| Comprehensive Income/Loss | $46.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $46.62M |
| Other Comprehensive Income/Loss | $130.38M |
| Other Comprehensive Income/Loss Attributable To Parent | $3.05M |